EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials.
Fabio ConfortiLaura PalaVincenzo BagnardiClaudia SpecchiaChiara OriecuiaAntonio MarraPaola ZagamiStefania MorgantiPaolo TarantinoChiara CataniaFilippo De MarinisPaola QueiroloTommaso Martino De PasPublished in: JNCI cancer spectrum (2020)
Patients with EGFR-mutated non small-cell lung cancer derived clinically meaningful larger PFS benefit from the addition of an anti-angiogenic drug to a first-generation EGFR-TKI at the cost of an increase of toxicities.